The European Medicines Agency has accepted the marketing authorization application for lesinurad (AstraZeneca), a gout treatment. According to results from some Phase 3 trials, lesinurad dropped the uric acid, which has been linked with painful gout flare-ups.

READ FULL ARTICLE Curated publisher From FierceBiotech